Home › Kanser sa Dugo › Massachusetts › Boston
Pag-aaral pangklinika para sa Kanser sa Dugo sa Boston, MA
Isang pag-aaral para sa Kanser sa Dugo ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Nagre-recruitObservasyonal na pag-aaral
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Nagre-recruitPhase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Nagre-recruit
- Massachusetts General Hospital, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Nagre-recruit
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- Beth Israel Deaconess Medical Center, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Dana Farber Cancer Institute, Boston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Nagre-recruitPhase 2
- Brigham and Women's Hospital, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Dana-Farber Cancer Institute, Boston
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Nagre-recruitPhase 3
- Tufts Medical Center, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
IVIG for Infection Prevention After CAR-T-Cell Therapy
Nagre-recruitPhase 2
- Massachusetts General Hospital Cancer Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Nagre-recruitObservasyonal na pag-aaral
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- Dana Farber Cancer Institute, Boston
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
Nagre-recruit
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Nagre-recruit
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Nagre-recruitPhase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Nagre-recruit
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Nagre-recruit
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Nagre-recruitPhase 1
- Dana-Farber Cancer Institute, Boston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Nagre-recruitPhase 1
- Dana-Farber Cancer Institute, Boston
Pag-aaral para sa Kanser sa Dugo sa ibang lungsod
- Houston, TX46 pag-aaral
- New York City, NY26 pag-aaral
- Washington, DC19 pag-aaral
- Seattle, WA18 pag-aaral
- Baltimore, MD18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Durham, NC16 pag-aaral
- Chicago, IL15 pag-aaral
- Philadelphia, PA14 pag-aaral
- Nashville, TN13 pag-aaral
- Edison, NJ13 pag-aaral
- Columbus, OH13 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso112 pag-aaral
- Non-Small Cell Lung Cancer90 pag-aaral
- Kanser (lahat ng uri)85 pag-aaral
- Metastatic Cancer63 pag-aaral
- Colorectal Cancer63 pag-aaral
- Kanser sa Baga62 pag-aaral
- Kanser sa Ovary61 pag-aaral
- Kanser sa Prostate59 pag-aaral
- Depression52 pag-aaral
- Kanser ng Endometrium50 pag-aaral
- Pagkabigo ng Puso44 pag-aaral
- Acute Myeloid Leukemia44 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.